Key facts
as of Sep 2026- CellCentric’s last known valuation is $382.5M (Apr 2025).
- It has raised $280.5M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($116.5M) in Apr 2025.
- Notable investors include Innovate UK, RA Capital Management, 5Y Capital, Future Planet Capital, Cambridge Enterprise Ventures — 20 tracked in total.
- 2 institutional filers report fund marks on CellCentric across 3 filings.
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for CellCentric
Recorded secondary trades
No secondary trades in CellCentric shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
2 filers · latest Jun 20262 SEC-registered funds reported 3 fair-value marks on CellCentric between May 2026 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
2 roundsAbout CellCentric
Operator of a clinical-stage cancer therapy biotechnology company intended to focus on novel drug development for specific cancers. The company's novel small-molecule inhibitors inhibit the common bromodomain of twin proteins down-regulate the androgen receptor and also deplete the adaptive AR splice variant forms, thereby enabling clients to treat specific cancers and notably relapsed refractory multiple myeloma.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2003
- Employees
- 46
- Website
- cellcentric.com/
- Ownership
- Privately Held (backing)